Please login to the form below

Not currently logged in
Email:
Password:

US bill will force disclosure of doctor payments

A bill introduced in the US Senate will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors

A bill introduced in the US Senate on 6 September 2007 will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors, according to the New York Times.

Companies with at least USD 100m in annual sales would have to disclose gifts or payments exceeding USD 25 in value each quarter, and the information would then be posted on a publicly accessible website.

Companies will have to disclose any payment or benefit made "directly, indirectly, through an agent, subsidiary or other third party", which might include payments by universities and by companies that organise conferences for Key Opinion Leaders (KOLs) with drug or medical device manufacturer funding.

Funding of continuing medical education programmes would also need to be disclosed. No-cost drug samples and financing for clinical trials would not have to be disclosed, according to the bill.

Senate Finance Committee member Chuck Grassley (Republican, Iowa), who is one of the bill's authors, said: "The public has no way to know whether a doctor's been given money that might affect prescribing habits."

Ken Johnson, senior vice-president of the Pharmaceutical Research and Manufacturers of America (PhRMA), countered: "A new law is not necessary when pharmaceutical marketing is already heavily regulated by the FDA."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics